✦ LIBER ✦

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

✍ Scribed by Nemanja Damjanov; Robert S. Kauffman; George T. Spencer-Green

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 142 KB
Volume: 60
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.24485

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of the efficacy and safety of

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

✍ Stanley B. Cohen; Tien-Tsai Cheng; Vishala Chindalore; Nemanja Damjanov; Ruben B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

The efficacy and safety of rituximab in

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

✍ Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

MLN3897 plus methotrexate in patients wi

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

✍ Clarissa E. Vergunst; Danielle M. Gerlag; Lisa von Moltke; Michael Karol; Tim Wy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). ## Methods In this phase IIa, proof‐of‐concept study, patients meeting the

The safety and efficacy of a JAK inhibit

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

✍ Joel M. Kremer; Bradley J. Bloom; Ferdinand C. Breedveld; John H. Coombs; Mark P 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views